16155-03-6

Basic information

• Product Name: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE
• Synonyms: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE;1-Methyl-4-(4-nitrophenyl)piperazine95%;1-METHYL-4-(4-NITROPHENYL)PIPERAZINE 95%;Piperazine, 1-Methyl-4-(4-nitrophenyl)-
• CAS NO: 16155-03-6
• Molecular Formula: C₁₁H₁₅N₃O₂
• Molecular Weight: 221.26
• Mol File: 16155-03-6.mol
• Article Data: 92

Chemical Properties

• Melting Point: 109-111°C
• Boiling Point: 369.5 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: /Solid
• Density: 1.198 g/cm³
• Vapor Pressure: 1.18E-05mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.41±0.42(Predicted)
• CAS DataBase Reference: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(16155-03-6)
• EPA Substance Registry System: 1-METHYL-4-(4-NITROPHENYL)PIPERAZINE(16155-03-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 16155-03-6(Hazardous Substances Data)

Usage

Description

1-Methyl-4-(4-nitrophenyl)piperazine is an organic compound characterized by its red solid appearance. It is a reagent with significant applications in the pharmaceutical industry, particularly in the development of inhibitors for targeted cancer treatments.

Uses

Used in Pharmaceutical Industry:
1-Methyl-4-(4-nitrophenyl)piperazine is used as a reagent for the preparation of diaminopyrimidines, which serve as reversible and irreversible inhibitors of mutant EGFR (epidermal growth factor receptor) tyrosine kinases. These inhibitors are crucial in the treatment of non-small-cell lung cancer, as they help regulate the abnormal cell growth associated with the disease.
Additionally, 1-Methyl-4-(4-nitrophenyl)piperazine is utilized in the preparation of disubstituted pyrimidine compounds. These compounds act as inhibitors for EGFR and/or ALK (anaplastic lymphoma kinase), which are relevant in the treatment of various diseases. By targeting these specific proteins, the compound can potentially improve therapeutic outcomes and provide more effective treatment options for patients.

InChI:InChI=1/C11H15N3O2/c1-12-6-8-13(9-7-12)10-2-4-11(5-3-10)14(15)16/h2-5H,6-9H2,1H3/p+1

Upstream product

• 109-01-3 1-methyl-piperazine 
• 586-78-7 para-nitrophenyl bromide 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 
• 74-88-4 methyl iodide 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 7440-44-0 pyrographite 
• 636-98-6 p-nitrobenzene iodide 
• 50-00-0 formaldehyd 
• 260252-87-7 4-(4'-nitrophenyl)piperazine hydrochloride 
• 321898-63-9 4-(4-nitrophenyl)piperazine-1-carbaldehyde 
• 463-57-0 methanediol 

Downstream Products

• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 106365-89-3 4-(4-methylpiperazin-1-yl)benzenethiol 
• 106365-99-5 2-(4-(4-methylpiperazino)phenylthio)benzoic acid 
• 106365-93-9 4'-(4-Methylpiperazino)phenyl 2,4-Dinitrophenyl Sulfide 
• 194799-59-2 4-(4-methyl-piperazino)-aniline; hydrochloride 
• 125819-00-3 4-(4-methyl-1-piperazinyl)benzenamine dihydrochloride 
• 760975-51-7 1,1-dimethyl-4-(4-nitrophenyl)piperazin-1-ium methyl sulphate 
• 1199795-12-4 1-methyl-4-{4-nitro-3-[(1-naphthalenesulfonyl)methyl]phenyl}piperazine 
• 1253422-19-3 C₁₈H₂₀ClN₃O₄S 
• 1253422-24-0 C₁₉H₂₃N₃O₄S 
• 1253422-26-2 C₁₆H₁₉N₃O₄S₂ 
• 1253422-27-3 C₁₈H₁₉Cl₂N₃O₄S 

Relevant articles and documents

Safety-catch linker strategies for the production of radiopharmaceuticals labeled with positron-emitting isotopes

A novel synthetic stratetegy for compounds labeled with the positron-emitting isotope carbon-11 is described. The use of precursors attached to a solid support via safety-catch linkers allows selective release of radiolabeled material, leaving unreacted precursor attached to the support. Two different linkers demonstrate the application to the preparation of radiolabeled N-alkyl tertiary amines and N-alkylsulfonamides. This technique is expected to lead to more widespread use of positron emission tomography for the in vivo analysis of compound behavior. Copyright

Discovery and in Vivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor

Cathepsin C (Cat C) participates in inflammation and immune regulation by affecting the activation of neutrophil serine proteases (NSPs). Therefore, cathepsin C is an attractive target for treatment of NSP-related inflammatory diseases. Here, the complete discovery process of the first potent "non-peptidyl non-covalent cathepsin C inhibitor"was described with hit finding, structure optimization, and lead discovery. Starting with hit 14, structure-based optimization and structure-activity relationship study were comprehensively carried out, and lead compound 54 was discovered as a potent drug-like cathepsin C inhibitor both in vivo and in vitro. Also, compound 54 (with cathepsin C Enz IC50 = 57.4 nM) exhibited effective anti-inflammatory activity in an animal model of chronic obstructive pulmonary disease. These results confirmed that the non-peptidyl and non-covalent derivative could be used as an effective cathepsin C inhibitor and encouraged us to continue further drug discovery on the basis of this finding.

NOTCH INHIBITORS AND USES THEREOF

Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.